Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.45 |
| ▸ | MMP1 | P03956 | 2/20 | 0.44 |
| ▸ | MMP13 | P45452 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3618418 | 1.00 | MAPK1 (0.47) | MAPK1SMN1; SMN2FKBP1ATSHRHIF1A | |
| SCHEMBL13547191 | 0.86 | SMN1; SMN2 (0.50) | MAPK1SMN1; SMN2FKBP1ATSHRHIF1A | |
| SCHEMBL13547190 | 0.86 | SMN1; SMN2 (0.50) | MAPK1SMN1; SMN2FKBP1ATSHRHIF1A | |
| SCHEMBL14218347 | 0.86 | SMN1; SMN2 (0.48) | MAPK1SMN1; SMN2TSHRSIGMAR1MEN1 | |
| SCHEMBL14218316 | 0.86 | SMN1; SMN2 (0.48) | MAPK1SMN1; SMN2TSHRSIGMAR1MEN1 | |
| SCHEMBL5640916 | 0.82 | SRC (0.58) | — | |
| SCHEMBL3610793 | 0.79 | SMN1; SMN2 (0.52) | MAPK1SMN1; SMN2FKBP1ATSHRHIF1A | |
| SCHEMBL3611571 | 0.79 | SMN1; SMN2 (0.52) | MAPK1SMN1; SMN2FKBP1ATSHRHIF1A | |
| SCHEMBL16466966 | 0.73 | GAA (0.49) | MAPK1SMN1; SMN2MMP1MMP13SIGMAR1 | |
| SCHEMBL14172059 | 0.73 | HDAC1 (0.43) | MAPK1TSHRKDM4EGAAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009957-A1 | NOVEL INHIBITORS OF BETA-LACTAMASE | MERCK SHARP & DOHME CORP. | 2010-01-14 | — | — | US | disclosed |
| EP-2069347-A2 | NOVEL INHIBITORS OF BETA-LACTAMASE | Merck & Co., Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008039420-A2 | NOVEL INHIBITORS OF BETA-LACTAMASE | MERCK & CO., INC. (US) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009957-A1 | NOVEL INHIBITORS OF BETA-LACTAMASE | MGAM, SI, MGAM2 | MAPK1 3643/4885SMN1; SMN2 3397/4885FKBP1A 2407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.